Skip to content

Efficacy and Safety of Radiofrequency Microneedling Combined with Mesotherapy versus Radiofrequency Microneedling in the Treatment of Periorbital Wrinkles

Efficacy and Safety of Radiofrequency Microneedling Combined with Mesotherapy versus Radiofrequency Microneedling in the Treatment of Periorbital Wrinkles

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102936
Enrollment
Unknown
Registered
2025-05-21
Start date
2025-06-15
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periorbital wrinkles

Interventions

Radiofrequency microneedling combined with mesotherapy group:Radiofrequency microneedling treatment once every 4 weeks, for a total of 3 treatments (at week 0, week 4, and week 8). Combined with: Meso
Radiofrequency microneedling group:Radiofrequency microneedling treatment once every 4 weeks, for a total of 3 treatments (at week 0, week 4, and week 8).

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged 35-65 years. 2.Patients have static wrinkles appearing on the periorbital skin, with or without symptoms of aging, laxity and hyperpigmentation. 3.Facial skin is essentially intact, with no significant inflammation, ulceration, or exudation. 4.The severity and distribution of periorbital wrinkles are symmetrical between the left and right eyes, with at least one periorbital area (lateral canthus, infraorbital region, or medial canthus) showing a grade I-II of Fitzpatrick Wrinkle and Elastosis Scale.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of dermal filler treatments or hyaluronic acid-based aesthetic procedures, as well as those who have undergone periocular rejuvenation therapies (e.g., laser, radiofrequency, focused ultrasound) within 6 months prior to enrollment. 2.Patients with a history of oral steroids, collagen, hyaluronic acid, or related cosmetic product use, as well as those taking skin growth-promoting supplements within 3 months prior to enrollment. 3.Patients with traumatic periocular lesions, infections, severe ocular diseases, or severe systemic diseases. 4.Patients with keloid-prone constitution. 5.Patients who are pregnant or in the lactation period. 6.Patients who currently involved in other clinical trial studies. 7.Patients whom the investigator deems unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
Fitzpatrick Wrinkle and Elastosis Scale Evaluation;

Secondary

MeasureTime frame
Erythema index;Skin thickness;Global Aesthetic Improvement Scale;Antera3D Wrinkles measurement;VISIA imaging;Skin hydration ;Melanin Index;Transepidermal water loss;Skin elasticity;

Countries

China

Contacts

Public ContactFenglin Zhuo

Beijing Friendship Hospital, Capital Medical University

zflsunny@hotmail.com+86 159 1089 5068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026